BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 25593071)

  • 1. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
    Li F; Chen G; Sheng C; Gusdon AM; Huang Y; Lv Z; Xu H; Xing M; Qu S
    Endocr Relat Cancer; 2015 Apr; 22(2):159-68. PubMed ID: 25593071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
    Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY
    Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.
    Ma YJ; Deng XL; Li HQ
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):591-599. PubMed ID: 26223933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
    Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
    Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
    Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF Status in Papillary Microcarcinomas of the Thyroid Gland: a Brief Review.
    Ieni A; Vita R; Cardia R; Giuffré G; Benvenga S; Tuccari G
    Curr Mol Med; 2019; 19(9):665-672. PubMed ID: 31625469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
    Shen G; Kou Y; Liu B; Huang R; Kuang A
    Nucl Med Commun; 2019 Jan; 40(1):8-13. PubMed ID: 30312216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of BRAF
    Attia AS; Hussein M; Issa PP; Elnahla A; Farhoud A; Magazine BM; Youssef MR; Aboueisha M; Shama M; Toraih E; Kandil E
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma.
    Kwak JY; Kim EK; Chung WY; Moon HJ; Kim MJ; Choi JR
    Radiology; 2009 Dec; 253(3):854-60. PubMed ID: 19710001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.
    Virk RK; Van Dyke AL; Finkelstein A; Prasad A; Gibson J; Hui P; Theoharis CG; Carling T; Roman SA; Sosa JA; Udelsman R; Prasad ML
    Mod Pathol; 2013 Jan; 26(1):62-70. PubMed ID: 22918165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
    Kim YS; Kim JS; Bae JS; Park WC
    World J Surg Oncol; 2013 May; 11():99. PubMed ID: 23687957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
    Bernstein J; Virk RK; Hui P; Prasad A; Westra WH; Tallini G; Adeniran AJ; Udelsman R; Sasaki CT; Roman SA; Sosa JA; Prasad ML
    Thyroid; 2013 Dec; 23(12):1525-31. PubMed ID: 23682579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
    Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
    Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma.
    Zhou YL; Zhang W; Gao EL; Dai XX; Yang H; Zhang XH; Wang OC
    Asian Pac J Cancer Prev; 2012; 13(4):1267-72. PubMed ID: 22799316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
    Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
    PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of BRAFV600E mutation with ultrasonographic features and clinicopathologic characteristics of papillary thyroid microcarcinoma: A retrospective study of 116 cases.
    Chen B; Zhang Z; Wang K; Shang M; Zhao S; Ding W; Du R; Yu Z; Xu X
    Clin Hemorheol Microcirc; 2019; 73(4):545-552. PubMed ID: 31306113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma.
    Kim KJ; Kim SG; Tan J; Shen X; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Xing M
    Eur J Cancer; 2020 Jan; 124():161-169. PubMed ID: 31790974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status.
    Mussazhanova Z; Matsuda K; Naruke Y; Mitsutake N; Stanojevic B; Rougounovitch T; Saenko V; Suzuki K; Nishihara E; Hirokawa M; Ito M; Nakashima M
    Histopathology; 2013 Nov; 63(5):726-34. PubMed ID: 24004175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.